Form 4: Illumina Director Philip Schiller Receives Restricted Stock Unit Grant

Illumina, Inc. Director Philip W. Schiller was granted 3,780 restricted stock units (RSUs) on May 21, 2025, as part of his compensation, increasing his total beneficial ownership to 20,148 units.

Summary

• Illumina, Inc. (ILMN) Director Philip W. Schiller was granted 3,780 restricted stock units (RSUs) on May 21, 2025.
• The RSUs were granted at a price of $0, which is typical for equity compensation grants.
• Following this transaction, Mr. Schiller's total beneficial ownership of Illumina common stock stands at 20,148 units.
• The 3,780 RSUs are subject to vesting, with 100% vesting on the earlier of the one-year anniversary of the grant date or the day immediately preceding the company's annual meeting for the year following the grant, provided Mr. Schiller continues to serve as a director.
• An adjustment related to Illumina's spin-out of Grail, Inc., completed on June 24, 2024, resulted in Mr. Schiller's unvested RSUs increasing by 53 units.

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (equity grant to a director), which is a standard compensation practice. It indicates continued alignment of management interests with shareholders but does not provide information on operational performance or strategic shifts that would significantly alter sentiment.

Positives

• The grant of restricted stock units aligns the director's interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• It represents a standard form of equity compensation for directors, indicating continuity in corporate governance and compensation practices.

Future Outlook

The vesting of the granted restricted stock units is contingent upon the director's continued service, with vesting expected on the earlier of the one-year anniversary of the grant or the date immediately preceding the company's annual meeting for the year following the grant.

Industry Context

The grant of restricted stock units to a director is a common practice in the life sciences and biotechnology industry, aligning executive and board member incentives with long-term shareholder value creation. This type of compensation is a standard component of corporate governance and executive remuneration packages across publicly traded companies.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) at a $0 price is a standard method of equity compensation for directors across various industries, including biotechnology and healthcare, similar to practices at companies like Thermo Fisher Scientific or Danaher Corporation, which also utilize equity grants to align director interests.
• The vesting schedule, tied to continued service and annual meeting dates, is a typical structure for director equity awards, ensuring retention and ongoing commitment, comparable to governance practices seen in large-cap companies globally.

Corporate Governance

Related Party Transactions

• Grant of 3,780 restricted stock units to Philip W. Schiller, a Director of Illumina, Inc., as part of his compensation package.

Stakeholder Impact

• Shareholders: The grant of RSUs represents a form of equity compensation that aligns the director's financial interests with the company's stock performance, potentially fostering decisions that benefit long-term shareholder value. It also implies a minor potential for future share dilution upon vesting.
• Director (Philip W. Schiller): Receives equity-based compensation, which incentivizes continued service and performance tied to the company's success.

Next Steps

• The granted restricted stock units will vest on the earlier of the one-year anniversary of the grant date (May 21, 2026) or the date immediately preceding the company's annual meeting for the year following the grant, provided Mr. Schiller remains a director.

Key Dates

Keywords

Illumina, ILMN, Form 4, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Philip W. Schiller, Equity Grant, Corporate Governance